SEC-sourced researchBeta
AWHL
Aspira Women's Health Inc.
Company comparison ↗
Data passport
- CIK
- 0000926617
- Exchange
- OTC
- Business activity
- In Vitro & In Vivo Diagnostic Substances · SIC 2835
- Financial inputs
- 6/6
- Filing date
- Oct 2, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 9,182,000.0000 | Apr 1, 2026 |
| December 2025 | 9,216,000.0000 | Apr 1, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 9,216,000.0000 | -12,780,000.0000 | -7,029,000.0000 | 5,456,000.0000 | 12,388,000.0000 | Apr 1, 2026 |
| December 2024 | 9,182,000.0000 | -13,094,000.0000 | -12,113,000.0000 | 5,491,000.0000 | 8,054,000.0000 | Apr 1, 2026 |
Explainable fundamental score
Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.
30/100
Profitability0
Growth50
Balance sheet0
Cash generation0
Data coverage100
Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $9.22M | Jan 1, 2025 – Dec 31, 2025 | Apr 1, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $9.18M | Jan 1, 2024 – Dec 31, 2024 | Apr 1, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$12.78M | Jan 1, 2025 – Dec 31, 2025 | Apr 1, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$7.03M | Jan 1, 2025 – Dec 31, 2025 | Apr 1, 2026 | 10-K |
| Total assetsAssets | $5.46M | Dec 31, 2025 | Apr 1, 2026 | 10-K |
| Total liabilitiesLiabilities | $12.39M | Dec 31, 2025 | Apr 1, 2026 | 10-K |
New filings
- 4AWHL · Aspira Women's Health Inc.Oct 2, 2026 · Other
- 10-QAWHL · Aspira Women's Health Inc.Aug 14, 2026 · Periodic
- 4/AAWHL · Aspira Women's Health Inc.Jul 17, 2026 · Other
- 4AWHL · Aspira Women's Health Inc.Jul 15, 2026 · Other
- 3AWHL · Aspira Women's Health Inc.Jul 15, 2026 · Other
- 8-KAWHL · Aspira Women's Health Inc.Jul 15, 2026 · Current event
- 8-K/AAWHL · Aspira Women's Health Inc.Jul 7, 2026 · Current event
- DAWHL · Aspira Women's Health Inc.Jun 22, 2026 · Other
- 8-KAWHL · Aspira Women's Health Inc.Jun 22, 2026 · Current event
- 8-KAWHL · Aspira Women's Health Inc.Jun 17, 2026 · Current event
- SCHEDULE 13D/AAWHL · Aspira Women's Health Inc.Jun 11, 2026 · Other
- 4AWHL · Aspira Women's Health Inc.Jun 9, 2026 · Other
- 8-KAWHL · Aspira Women's Health Inc.Jun 9, 2026 · Current event
- 4AWHL · Aspira Women's Health Inc.May 29, 2026 · Other
- 4/AAWHL · Aspira Women's Health Inc.May 29, 2026 · Other
- 4/AAWHL · Aspira Women's Health Inc.May 29, 2026 · Other
- DEFA14AAWHL · Aspira Women's Health Inc.May 29, 2026 · Other
- 8-KAWHL · Aspira Women's Health Inc.May 26, 2026 · Current event
- 10-QAWHL · Aspira Women's Health Inc.May 15, 2026 · Periodic
- 8-KAWHL · Aspira Women's Health Inc.Apr 30, 2026 · Current event